Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Natural History of Systemic and Nasal Mucosal Immunity After Influenza Vaccination in a Pediatric Population

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04963166
Recruitment Status : Recruiting
First Posted : July 15, 2021
Last Update Posted : January 14, 2022
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Institute of Allergy and Infectious Diseases (NIAID) )

Tracking Information
First Submitted Date July 14, 2021
First Posted Date July 15, 2021
Last Update Posted Date January 14, 2022
Estimated Study Start Date January 19, 2022
Estimated Primary Completion Date December 31, 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: July 29, 2021)
  • Baseline and post-vaccination (6 weeks) systemic anti-influenza antibodies as measured by: 1. Anti-HA head antibody quantitative ELISA IgM, IgG, IgA 2. Anti-HA stalk antibody quantitative ELISA IgM, IgG, IgA 3. Anti-NA antibody quantitative ELIS... [ Time Frame: 6 weeks ]
    HA and NA antibodies are known correlates of protection.
  • Baseline and post-vaccination (6 weeks) mucosal anti-influenza antibodies from nasal samples as measured by: 1. Anti-HA head antibody quantitative ELISA IgA, IgG 2. Anti-HA stalk antibody quantitative ELISA IgA IgG 3. Anti-NA antibody quantitati... [ Time Frame: 6 weeks ]
    HA and NA antibodies are known correlates of protection.
Original Primary Outcome Measures
 (submitted: July 14, 2021)
  • Characterize nasal mucosal humoral immune response pre and post influenza vaccination [ Time Frame: Baseline and post-vaccination (Week 6) mucosal anti-influenza antibodies ]
    1. Anti-HA head antibody quantitative ELISA IgA, IgG; 2. Anti-HA stalk antibody quantitative ELISA IgA IgG 3. Anti-NA antibody quantitative ELISA IgA, IgG
  • Characterize systemic humoral immune response pre and post influenza vaccination [ Time Frame: Baseline and post-vaccination (Week 6) systemic anti-influenza antibodies ]
    1. Anti-HA head antibody quantitative ELISA IgM, IgG, IgA 2. Anti-HA stalk antibody quantitative ELISA IgM, IgG, IgA 3. Anti-NA antibody quantitative ELISA IgM, IgG, IgA
Change History
Current Secondary Outcome Measures Not Provided
Original Secondary Outcome Measures
 (submitted: July 14, 2021)
Describe the trend of nasal mucosal and serum humoral immune response over time after vaccination [ Time Frame: Multiple timepoint measurements of mucosal anti-influenza antibodies from nasal samples and systemic (Day 10, Week 6, Week 24) ]
1. Anti-HA head antibody quantitative ELISA IgA, IgG, IgM (systemic only) 2. Anti-HA stalk antibody quantitative ELISA IgA, IgG, IgM (systemic only) 3. Anti-NA antibody quantitative ELISA IgA, IgG, IgM (systemic only)
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Natural History of Systemic and Nasal Mucosal Immunity After Influenza Vaccination in a Pediatric Population
Official Title Natural History of Systemic and Nasal Mucosal Immunity After Influenza Vaccination in a Pediatric Population
Brief Summary

Background:

The influenza (flu) virus infects millions around the world every year. Children are at increased risk of complications from the flu. The flu vaccine protects against influenza, but the vaccine can be improved. Researchers want to learn more about children s mucosal and systemic immunity after flu vaccination. This could help to develop more effective flu vaccines in the future.

Objective:

To learn what happens in kids immune systems after receiving a flu vaccine.

Eligibility:

Children ages 2-17 who have received a flu vaccine in the past and plan to get the current seasonal flu vaccine given by injection.

Design:

All study visits will take place at home and communication with the study team will be done via phone or videoconference.

Participants will review medical history and flu vaccination history with the study team.

Participants will get the flu vaccine at their local doctor s office or pharmacy. They will not be given the vaccine in this study.

Participants will complete an electronic survey to give details about the date and type of flu vaccine received.

Participants will collect nasal and fingerstick samples at home. They will collect 4 nasal samples and 3 fingerstick samples over 6 months: once before they get the flu vaccine and 2-3 times after they get the vaccine. They will use collection kits that include instructions, sample collection supplies, and shipping materials. They will ship all samples back to NIH with all costs covered by NIH.

Participation will last for 6 months.

Compensation is provided.

Detailed Description

Title:

Natural History of Systemic and Nasal Mucosal Immunity after Influenza Vaccination in a Pediatric Population

Study Description:

While adults are heavily represented in influenza vaccine studies, there are limited studies in the pediatric population. This study will characterize the changes in nasal and systemic immunity after influenza vaccination in a pediatric population.

Objectives:

Primary Objectives:

Characterize nasal mucosal humoral immune response pre and post influenza vaccination

Characterize systemic humoral immune response pre and post influenza vaccination

Secondary Objectives:

Describe the trend of nasal mucosal mucosal and serum humoral immune response over time after vaccination

Endpoints:

Primary Endpoints:

  1. Baseline and post-vaccination mucosal anti-influenza antibodies from nasal samples as measured by:

    1. Anti-hemagglutination (HA) head antibody quantitative enzyme-linked immunosorbent assay (ELISA) immunoglobulins (Ig) (IgA, IgG)
    2. Anti-HA stalk antibody quantitative ELISA (IgA, IgG)
    3. Anti-neuraminidase (NA) antibody quantitative ELISA (IgA, IgG)
  2. Baseline and post-vaccination systemic anti-influenza antibodies as measured by:

    1. Anti-HA head antibody quantitative ELISA (IgM, IgG, IgA)
    2. Anti-HA stalk antibody quantitative ELISA (IgM, IgG, IgA)
    3. Anti-NA antibody quantitative ELISA (IgM, IgG, IgA)

Secondary Endpoints:

Multiple timepoint measurements of mucosal anti-influenza antibodies from nasal samples as measured by:

Anti-HA head antibody quantitative ELISA (IgA, IgG)

Anti-HA stalk antibody quantitative ELISA (IgA, IgG)

Anti-NA antibody quantitative ELISA (IgA, IgG)

Multiple timepoint measurements of systemic anti-influenza antibodies as measured by:

Anti-HA head antibody quantitative ELISA (IgM, IgG, IgA)

Anti-HA stalk antibody quantitative ELISA (IgM, IgG, IgA)

Anti-NA antibody quantitative ELISA (IgM, IgG, IgA)

Study Population:

Children who are >= 2 years and < 18 years of age (N = 51; accrual ceiling = 100). Participants will be enrolled by age group: 2 - 6 years old, 7 - 11 years old and 12 - 17 years old with a goal enrollment of 17 per group.

Description of Sites/Facilities Enrolling Participants:

Participants will be enrolled by telephone or videoconference, and sample collections will be done in participant homes. Recruitment will be from community pediatric clinics and self- or family referral.

Study Duration:

2 years

Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population Children receiving their first ever influenza vaccine require two doses of the vaccine one month apart and will not be included in this study. Only participants who have already received a flu vaccine series in the past will be eligible for this study. Evaluation of immunity after the first ever influenza vaccination series is an important question that should be explored separately. We will enroll participants into one of three cohorts by age: 2 6 years old, 7 11 years old, and 12 17 years old. We will aim to enroll similar numbers of participants into each group to ensure a diverse age range in our population.
Condition Influenza Immunity
Intervention Not Provided
Study Groups/Cohorts
  • Cohort 1
    2 - 6 year olds
  • Cohort 2
    7 - 11 year olds
  • Cohort 3
    12 - 17 year olds
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Recruiting
Estimated Enrollment
 (submitted: July 14, 2021)
100
Original Estimated Enrollment Same as current
Estimated Study Completion Date December 31, 2022
Estimated Primary Completion Date December 31, 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria
  • INCLUSION CRITERIA:

In order to be eligible to enroll in this study, an individual must meet all of the following criteria:

  • >= 2 years of age and < 18 years of age at the time of enrollment.
  • Completed a previous influenza series in the past and therefore requires only one seasonal influenza vaccine every year.
  • Planning to receive the current seasonal inactivated influenza vaccine given by injection.
  • Parent or guardian willing and able to provide verbal consent.
  • Willing and able to undergo home blood micro-sampling and nasal sampling.
  • Willing to have samples stored for future research.
  • Parent/guardian able to proficiently speak, read, and write English.

EXCLUSION CRITERIA:

Any individual who meets any of the following criteria will be excluded from participation in this study:

  • Already received the current season s influenza vaccine.
  • Planning to receive the current seasonal live attenuated influenza vaccine (LAIV).
  • Self-reported pregnancy or breastfeeding.
  • Any condition that, in the opinion of the investigator, would compromise the safety of the study participant or staff, or would prevent proper conduct of the study.
Sex/Gender
Sexes Eligible for Study: All
Ages 2 Years to 17 Years   (Child)
Accepts Healthy Volunteers Yes
Contacts
Contact: Alison Han, M.D. (301) 480-5722 alison.han@nih.gov
Listed Location Countries United States
Removed Location Countries  
 
Administrative Information
NCT Number NCT04963166
Other Study ID Numbers 10000488
000488-I
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement Not Provided
Responsible Party National Institutes of Health Clinical Center (CC) ( National Institute of Allergy and Infectious Diseases (NIAID) )
Study Sponsor National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators Not Provided
Investigators
Principal Investigator: Alison Han, M.D. National Institute of Allergy and Infectious Diseases (NIAID)
PRS Account National Institutes of Health Clinical Center (CC)
Verification Date August 19, 2021